However, the prognosis for patients with brain metastases remains quite poor, and overall survival is mainly influenced by the molecular phenotype of breast cancer, with triple-negative/basal-like tumors having the worst outcomes and HER-2-enriched ones having the best. This evidence concerns the gene ERBB2 and breast cancer.